Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0002023658-25-000039
Filing Date
2025-05-13
Accepted
2025-05-13 16:12:04
Documents
62
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q bcax-20250331.htm   iXBRL 10-Q 1747206
2 EX-31.1 exhibit311q125.htm EX-31.1 10535
3 EX-31.2 exhibit312q12025.htm EX-31.2 10519
4 EX-32.1 exhibit321q125.htm EX-32.1 7704
  Complete submission text file 0002023658-25-000039.txt   5663418

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bcax-20250331.xsd EX-101.SCH 33334
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT bcax-20250331_cal.xml EX-101.CAL 37449
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT bcax-20250331_def.xml EX-101.DEF 192488
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bcax-20250331_lab.xml EX-101.LAB 469495
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bcax-20250331_pre.xml EX-101.PRE 336525
65 EXTRACTED XBRL INSTANCE DOCUMENT bcax-20250331_htm.xml XML 431100
Mailing Address 245 MAIN STREET CAMBRIDGE MA 02142
Business Address 245 MAIN STREET CAMBRIDGE MA 02142 617-785-8308
Bicara Therapeutics Inc. (Filer) CIK: 0002023658 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-42271 | Film No.: 25940219
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)